Presentations from German group Bayer (BAYN: DE) at the JP Morgan Healthcare Conference have rallied investors’ confidence in the company’s mid-term prospects.
Interest in the firm has been depressed by legal battles stemming from its chemicals and crop science interests, connected with the weedkiller Roundup and with polychlorinated biphenyl (PCB)-based products.
Now, a more positive outlook for the group’s pharmaceuticals division has raised the prospect that the company could be undervalued at present.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze